Francisco Javier Ramírez Godinez

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 284 citations · Full text

Medicine, Oncology, Pharmacology +13

Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial

Bradley J. Monk, Takafumi Toita, Xiaohua Wu et al. · The Lancet Oncology · 2023 · 204 citations

Medicine, Oncology, Pharmacotherapy +12

Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study

Myung‐Ju Ahn, Kentaro Tanaka, Luis Paz‐Ares et al. · Journal of Clinical Oncology · 2024 · 182 citations · Full text

Medicine, Oncology, Pharmacology +9

Trastuzumab Deruxtecan in Residual HER2-Positive Early Breast Cancer

Sibylle Loibl, Yeon Hee Park, Zhi‐Ming Shao et al. · New England Journal of Medicine · 2025 · 30 citations

Medicine, Oncology, Pharmacology +17

Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyses

Jyoti Mayadev, Juan Carlos Vázquez Limón, Francisco Javier Ramírez Godinez et al. · Annals of Oncology · 2025 · 14 citations · Full text

Medicine, Oncology, Radiation Oncology +17